arrow
I

Ignacio Durán

hospital universitario marques de valdecilla
H指数:54
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CABOPRE: Evaluating Perioperative Cabozantinib’s Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma

CABOPRE:评估围手术期卡博替尼对晚期肾细胞癌细胞减灭性肾切除术的疗效及生物标志物

Cancers
IF4.4
2026-10-060
OA
A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract

TROPiCS-04研究的通俗语言摘要:沙西妥珠单抗在铂类化疗和免疫疗法之后,用于患有膀胱、尿道或上尿路局部晚期或转移性癌症的人群

2025-11-011
PRE
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial

针对晚期尿路上皮癌的一线治疗方案:比较三周期与六周期铂类化疗后接受阿维鲁zumab维持治疗的疗效——II期DISCUS试验

2025-10-170
OAAI
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial

Sacituzumab govitecan在晚期尿路上皮癌中的应用:TROPiCS-04,一项III期随机试验

2025-02-014
PRE
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌: imvior210 II期临床试验的最终分析

2024-12-010
PRE
BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

BT8009单药治疗在enfotumab vedotin(EV)初治患者(pts)中的转移性尿路上皮癌(mUC):Duravelo-1研究的更新结果

2024-09-012
PRE
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy

EV-301既往接受过治疗的晚期尿路上皮癌患者的健康相关生活质量: Enfortumab Vedotin与化疗的3期试验

2024-06-014
OAAI
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Enfortumab Vedotin和Pembrolizumab在未经治疗的晚期尿路上皮癌中的应用

2024-03-07153
PRE
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
2023-11-030
OAAI
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

晚期前列腺癌-转移性和/或去势抵抗性前列腺癌患者的管理: 晚期前列腺癌共识会议 (APCCC) 2022的报告

2023-05-0166
OA
Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
2023-04-017
OAAI
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

晚期前列腺癌患者的管理。第一部分: 中/高危和局部晚期疾病,生化复发和激素治疗的副作用: 晚期前列腺癌共识会议2022的报告

2023-03-0164
OA
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

转移性去势抵抗性前列腺癌患者疾病进展为醋酸阿比特龙加泼尼松后,醋酸阿比特龙加泼尼松联合多西他赛或多西他赛加泼尼松的II期随机试验: ABIDO-SOGUG试验

2022-11-017
OAAI
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
2022-08-0182
OA
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (vol 82, pg 6, 2022)

新型冠状病毒肺炎大流行期间专家对前列腺癌管理的看法: 2021高级前列腺癌共识会议的报告 (第82卷,第6页,2022页)

2022-07-010
OA
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

新型冠状病毒肺炎大流行期间专家对前列腺癌管理的看法: 高级前列腺癌共识会议2021的报告

2022-07-016
OA
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

晚期前列腺癌患者的管理: 2021晚期前列腺癌共识会议的报告

2022-07-0165
OA